LEO Pharma reveals winning entry for innovation award

 20 February 2013, Denmark - LEO Pharma can reveal this year’s winning entry for its annual innovation award, open to Denmark’s top life-science and business students.

The project, ‘KIX, novel and innovative drug for treatment of degenerative bone-disorder’, was selected amongst many entries as best business plan for its excellent market understanding.

The award is open to students taking the MSc in Bioentrepreneurship – part of the BioBusiness and Innovation Program, co-founded and co-sponsored by LEO Pharma and other life-science companies.

“LEO Pharma is proud to present this award to students on the BioBusiness and Innovation Program,” says Kim Kjoeller, Senior Vice President, Global Development.

“The life-science industry needs people who not only understand the science behind new developments, but also the complex commercial processes. The award winners demonstrated this knowledge mix, which is essential for future life-science pioneers.”

We use cookies on this website

The cookies help us gain a better understanding of how you use our website; display applications and functionalities, to optimise your website experience, to assign a unique identification number to you, and to help you remember your user ID and password when you return to the website. We also use cookies to generate statistical information.

By continuing to browse our website, you are agreeing to our use of cookies

If you want to know more about our cookie policy and how to avoid and delete cookies click here.